vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and HWH International Inc. (HWH). Click either name above to swap in a different company.
HWH International Inc. is the larger business by last-quarter revenue ($206.8K vs $169.0K, roughly 1.2× Aligos Therapeutics, Inc.). On growth, HWH International Inc. posted the faster year-over-year revenue change (-40.2% vs -72.1%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
HWH International Inc operates in the global luxury hospitality and lifestyle services industry, providing premium travel membership programs, curated high-end travel experiences, and exclusive access to luxury resorts, fine dining venues, and premium leisure facilities. Its key markets include North America, Asia Pacific, and Europe, serving high-net-worth individuals and corporate clients.
ALGS vs HWH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $206.8K |
| Net Profit | — | $-291.0K |
| Gross Margin | — | 59.8% |
| Operating Margin | — | -142.7% |
| Net Margin | — | -140.7% |
| Revenue YoY | -72.1% | -40.2% |
| Net Profit YoY | 75.8% | 46.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | $206.8K | ||
| Q2 25 | $965.0K | $310.4K | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | $287.1K | ||
| Q3 24 | $1.3M | $345.5K | ||
| Q2 24 | $1.1M | $334.9K | ||
| Q1 24 | $694.0K | $286.1K |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-291.0K | ||
| Q2 25 | $-15.9M | $83.4K | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | $-476.7K | ||
| Q3 24 | $-19.3M | $-548.5K | ||
| Q2 24 | $5.1M | $-387.9K | ||
| Q1 24 | $-34.9M | $-1.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | 59.8% | ||
| Q2 25 | — | 48.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 46.3% | ||
| Q2 24 | — | 49.2% | ||
| Q1 24 | — | 57.1% |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -142.7% | ||
| Q2 25 | -1924.0% | 24.5% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | -170.2% | ||
| Q3 24 | -1610.5% | -155.5% | ||
| Q2 24 | -2489.5% | -120.5% | ||
| Q1 24 | -3176.7% | -467.1% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -140.7% | ||
| Q2 25 | -1643.8% | 26.9% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | -166.1% | ||
| Q3 24 | -1540.7% | -158.7% | ||
| Q2 24 | 477.0% | -115.8% | ||
| Q1 24 | -5023.5% | -467.2% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $2.8M |
| Total Assets | $88.5M | $5.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | $2.9M | ||
| Q2 25 | $122.9M | $3.7M | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | $4.4M | ||
| Q3 24 | $74.9M | $836.3K | ||
| Q2 24 | $94.5M | $958.9K | ||
| Q1 24 | $112.7M | $1.1M |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | $2.8M | ||
| Q2 25 | $101.9M | $3.2M | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | $2.8M | ||
| Q3 24 | $50.1M | $-374.9K | ||
| Q2 24 | $67.2M | $-3.6M | ||
| Q1 24 | $59.8M | $-3.1M |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | $5.2M | ||
| Q2 25 | $134.7M | $10.6M | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | $6.4M | ||
| Q3 24 | $88.4M | $2.9M | ||
| Q2 24 | $108.8M | $3.1M | ||
| Q1 24 | $127.9M | $2.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-199.9K |
| Free Cash FlowOCF − Capex | — | $-217.9K |
| FCF MarginFCF / Revenue | — | -105.4% |
| Capex IntensityCapex / Revenue | — | 8.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | $-199.9K | ||
| Q2 25 | $-15.5M | $26.9K | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | $-415.2K | ||
| Q3 24 | $-20.1M | $-275.0K | ||
| Q2 24 | $-19.5M | $-490.8K | ||
| Q1 24 | $-22.7M | $-638.2K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-217.9K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-415.5K | ||
| Q3 24 | — | $-277.1K | ||
| Q2 24 | — | $-516.8K | ||
| Q1 24 | — | $-640.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | -105.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -144.7% | ||
| Q3 24 | — | -80.2% | ||
| Q2 24 | — | -154.3% | ||
| Q1 24 | — | -223.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
